Forest Buys Clinical Data And Extends Its Antidepressant Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The Lexapro maker will pay $1.2 billion upfront plus potential milestones to gain a recently approved antidepressant Viibryd.